NCT04094311 2026-02-17Study of Out of Specification for TisagenlecleucelNovartisPhase 3 Recruiting200 enrolled
NCT06408194 2026-02-10Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell MalignanciesStanford UniversityPhase 1 Recruiting20 enrolled
NCT05541341 2025-06-06Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte MalignanciesNovartisRecruiting200 enrolled